JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]-JNJ-70099731 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [18F]-JNJ-70099731

First Posted Date: 2021-06-03

Last Posted Date: 2023-02-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 13

Registration Number: NCT04911543

Locations: 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium

A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever

Phase 2

Terminated

Conditions: Dengue

Interventions: Drug: JNJ-64281802
Drug: Placebo

First Posted Date: 2021-05-28

Last Posted Date: 2024-03-01

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 5

Registration Number: NCT04906980

Locations: 🇸🇬
Singapore General Hospital, Singapore, Singapore

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

Phase 1

Recruiting

Conditions: Prostatic Neoplasms

Interventions: Drug: JNJ-78278343

First Posted Date: 2021-05-24

Last Posted Date: 2025-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 260

Registration Number: NCT04898634

Locations: 🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳
Sun Yat-Sen University Cancer Center, Guang Zhou Shi, China
🇯🇵
Yokohama City University Medical Center, Yokohama, Japan

and more 13 locations

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

Phase 3

Recruiting

Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

Interventions: Biological: ExPEC9V
Other: Placebo

First Posted Date: 2021-05-24

Last Posted Date: 2025-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 18556

Registration Number: NCT04899336

Locations: 🇬🇧
North Tees Furturemeds, Stockton-on-Tees, United Kingdom
🇺🇸
Lakeview Clinical Research, Guntersville, Alabama, United States
🇺🇸
Hope Research Institute, Las Vegas, Nevada, United States

and more 341 locations

A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus

Phase 2

Active, not recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Other: Placebo
Drug: Nipocalimab
Drug: Standard-of-care treatment

First Posted Date: 2021-05-12

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 228

Registration Number: NCT04882878

Locations: 🇺🇦
Medbud-Clinic LLC, Kyiv, Ukraine
🇧🇬
UMHAT St. Ivan Rilski, Sofia, Bulgaria
🇺🇸
Valerius Medical Group & Research Center, Los Alamitos, California, United States

and more 83 locations

A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis

Phase 2

Not yet recruiting

Conditions: Lupus Nephritis

Interventions: Other: Placebo
Drug: Nipocalimab
Drug: Standard-of-care treatment

First Posted Date: 2021-05-12

Last Posted Date: 2025-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 80

Registration Number: NCT04883619

Locations: 🇺🇸
Omega Research Consultants, DeBary, Florida, United States
🇺🇸
Valerius Medical Group & Research Center, Los Alamitos, California, United States
🇺🇸
Respire Research, LLC, Palm Springs, California, United States

and more 8 locations

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

Phase 3

Active, not recruiting

Conditions: Arthritis, Psoriatic

Interventions: Drug: Guselkumab
Drug: Placebo

First Posted Date: 2021-05-11

Last Posted Date: 2025-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 1054

Registration Number: NCT04882098

Locations: 🇺🇦
Komunalnyi zaklad Kryvorizka miska klinichna likarnia #2 Dnipropetrovskoi oblasnoi rady, Kryvyi Rih, Ukraine
🇺🇦
Khmelnitska oblasna likarnia, Khmelnitsky, Ukraine
🇺🇦
Derzhavna ustanova Natsionalnyi instytut terapii imeni L.T.Maloi NAMN Ukrainy viddil klinichnoi, Kharkiv, Ukraine

and more 266 locations

A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

Phase 1

Active, not recruiting

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Non-Hodgkin

Interventions: Drug: JNJ-67856633
Drug: Ibrutinib

First Posted Date: 2021-05-06

Last Posted Date: 2025-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 45

Registration Number: NCT04876092

Locations: 🇫🇷
Institut Paoli Calmettes, Marseille, France
🇫🇷
Hopital St Louis, Paris, France
🇩🇰
Rigshospitalet, Copenhagen, Denmark

and more 7 locations

A Study of JNJ-56136379 in Healthy Participants

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: JNJ-56136379
Drug: Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)

First Posted Date: 2021-04-21

Last Posted Date: 2021-07-15

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT04853524

A Study of Nipocalimab in Healthy Male and Female Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Nipocalimab
Other: Placebo

First Posted Date: 2021-04-19

Last Posted Date: 2023-07-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 89

Registration Number: NCT04848558

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy